Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Author:

Gordon, Lori A

Kumar, Parag

Brooks, Kristina M

Kellogg, Anela

McManus, Maryellen

Alfaro, Raul M

Nghiem, Khanh

George, Jomy M

Lozier, Jay

Penzak, Scott R

Hadigan, Colleen
Author Address

From Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.)., From Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.). Parag.kumar@nih.gov.,

Author Address